Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas
| Autor: | Carlos K. H. Wong, Herbert Ho-Fung Loong, Sampson Sui Chun Kwan, Y.-M. Lau, Gordon C.H. Tang, Linda K.S. Leung, Teresa Tse, Yingjun Zhang, Yihui Wei |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty sarcoma Population Comorbidity comorbidities lcsh:RC254-282 survival peripheral blood indices Internal medicine Diabetes mellitus Prevalence Medicine Humans In patient Lymphocytes education Original Research education.field_of_study business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Peripheral blood Oncology Cohort Sarcoma prognosis business Comorbidity index |
| Zdroj: | ESMO Open ESMO Open, Vol 5, Iss 6 (2020) |
| ISSN: | 2059-7029 |
| Popis: | Background The prognostic impact of comorbidities in patients with sarcomas is not well defined. The aims of this study were to examine the implications of comorbidities and abnormal peripheral blood indices in patients with sarcomas.Methods A population-based database was assembled to extract patients with sarcoma in Hong Kong between January 2004 and March 2018. Charlson’s Comorbidity Index (CCI) score and prevalence of comorbidities, neutrophil, lymphocyte and platelet counts at diagnosis were assessed. The prognostic values of CCI, neutrophil-lymphocyte (NLR) and platelet-lymphocyte ratios (PLR) were estimated using Cox proportional hazard models. Restricted cubic spline plots were used to explore the association of baseline NLR and PLR with all-cause and cancer-specific mortality.Results Among 3358 eligible patients with sarcomas, 52.2% died after a median 26 months of follow-up. The most common comorbidities were diabetes mellitus (9.8%) and cerebrovascular disease (4.8%). Patients with higher CCI had higher mortality (CCI=3 vs CCI=2; HR 1.49; 95% CI 1.19 to 1.87; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|